| Ticker: | IVVD |
| Current Price: | $0.58 |
| % Daily Change: | 2.61% |
| Volume (1,000s): | 3,155.03 |
| Average Volume (1,000s): | 0.00 |
| Market Cap (M): | $171.58 |
| 1/2/2024 Price: | $0.56 |
| Change Since Inception: | 3.57% |
205 Church Street
New Haven, CT 06510
United States
Invivyd, Inc. (NASDAQ: IVVD) develops monoclonal antibodies to protect people from serious viral infections. Its first product, PEMGARDA (pemivibart), is available in the U.S. under emergency use authorization for pre-exposure prevention of COVID-19 in certain immunocompromised adults and adolescents, and brought in $14.3 million in net product revenue in the second quarter of 2026. Its lead candidate, VYD2311, is a vaccine-alternative antibody built on the same backbone as pemivibart. It holds FDA Fast Track designation and is completing the pivotal Phase 3 DECLARATION trial, which is designed to support a Biologics License Application, with top-line data expected around the end of the third quarter of 2026. The company is also exploring antibodies for RSV and measles. Formerly Adagio Therapeutics, Invivyd was incorporated in 2020 and is headquartered in New Haven, Connecticut.